- Clovis Oncology recently reported impressive data from their ATHENA-MONO Phase III study. The ATHENA-MONO data should support the use of Rubraca in the first-line ovarian setting.
- The company is scheduled to report data from two more Phase III studies for Rubraca this year.
- Clovis has a chance to be a leader in targeted radionuclide therapies. FAP-2286 is the company's lead FAP program and will be the first TRT to enter the clinic.
- It is time to take on a fresh perspective. The company’s recent earnings report and company updates hold key materials required to forge a new thesis for CLVS.
- CLVS is now trading up on the ATHENA-MONO news and is starting to break long-term downtrends on both the Monthly and Daily charts.
For further details see:
Clovis Oncology: Forging A Fresh Perspective